NCT06701344View on ClinicalTrials.gov

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

May 4, 2026

Study Completion Date

December 4, 2027

Conditions
Enteropathy Associated T Cell Lymphoma
Interventions
DRUG

Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)

"Induction Treatment:~Golidocitinib:150mg QD Cyclophosphamide:750mg/m2，d1 vincristine:1.4mg/m2，d1(max 2mg) doxorubicin:50mg/m2，d1 Prednisone:60mg/m2 (max 100mg)，d1-d5 Every 21 days"

DRUG

Golidocitinib

"Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT."

All Listed Sponsors
lead

Ruijin Hospital

OTHER